Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan 17:45:e00687.
doi: 10.1016/j.crwh.2025.e00687. eCollection 2025 Mar.

Etonogestrel implant failure in a woman taking thyroid hormone replacement: A case report

Alice Moylan  1 , Jewel Brown  2 , Melissa J Chen  1   2 , Mitchell D Creinin  1   2
Affiliations
Case Reports

Etonogestrel implant failure in a woman taking thyroid hormone replacement: A case report

Alice Moylan et al. Case Rep Womens Health. .

Abstract

The etonogestrel implant is known to have high contraceptive efficacy for up to 5 years. This case report describes etonogestrel implant failure during year 4 of use in a patient with a normal body mass index. The patient was receiving thyroid hormone replacement after a thyroidectomy and was found to have iatrogenic thyrotoxicosis in the months preceding pregnancy. Further study of the effects of thyroid hormone on etonogestrel metabolism are indicated.

Keywords: Contraceptive implant; Etonogestrel; Hyperthyroidism; Pregnancy.

PubMed Disclaimer

References

    1. Darney P., Patel A., Rosen K., Shapiro L.S., Kaunitz A.M. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil. Steril. 2009;19(5):1646–1653. doi: 10.1016/j.fertnstert.2008.02.140. - DOI - PubMed
    1. Nexplanon [package insert] Merck Sharp & Dohme B.V., A Subsidiary of Merck & Co., Inc.; 2011. US Food and Drug Administration Website.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021529s018lbl.pdf [Revised October 2018]. Available from:
    1. McNicholas C., Swo E., Wan L., Peipert J.F. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration–approved duration. Am. J. Obstet. Gynecol. 2017;216(6) doi: 10.1016/j.ajog.2017.01.036. 586.e1-e6. - DOI - PMC - PubMed
    1. Ali M., Akin A., Bahamondes L., Brache V., Habib N., Landoulsi S., Hubacher D. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum. Reprod. 2016;31(11):2491–2498. doi: 10.1093/humrep/dew222. - DOI - PMC - PubMed
    1. Harrison-Woolrych M., Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception. 2005;71(4):306–308. doi: 10.1016/j.contraception.2004.10.005. - DOI - PubMed

Publication types

LinkOut - more resources